Sanofi shares down after FDA rejection
29735
Investors wiped some 6 billion euros ($7.97 billion) off the market value of French pharmaceutical company Sanofi-Aventis Thursday after U.S. federal health advisers rejected its Accomplia weight-loss drug.
167015
PARIS/LONDON  - Sanofi-Aventis shares rose on   Friday after a U.S. judge blocked further sales of generic   Plavix, but gains were capped as it warned cheap supplies of   the blood-thinner already in the market would hit 2006 profits.
454431
The drug company's experimental treatment for Alzheimer's  failed to prove effective in a big clinical trial. The stock  closed Tuesday at $45.85 on the New York Stock Exchange before  falling 10 percent in after-hours trading following release of  the trial results.
134737
Shares of Pharmos Corp. PARS.O fell  57 percent before the bell on Monday after the  biopharmaceutical company said clinical trials showed its drug  dexanabinol was not effective as a treatment for severe  traumatic brain injury.
301064
A U.S. judge on Thursday granted a   request from Sanofi-Aventis and Bristol-Myers Squibb Co. to   block the sale of a generic form of their top-selling Plavix   blood thinner.
233492
Shares in drug giant AstraZeneca fall after a US medical panel recommends that regulators reject its new drug Exanta.
64708
Shares of Merck &amp; Co. plunged nearly 27 percent yesterday, pulling other stocks down with it, after the pharmaceutical giant yanked its Vioxx arthritis drug off the market because of heart safety concerns.
22568
AstraZeneca Plc suffered its third  setback in two months on Friday as lung cancer drug Iressa  failed to help patients live longer in a major clinical trial,  sending its shares down as much as 9.2 percent.
81475
Stocks were knocked lower on Thursday  as investors worried that rising prices for oil and commodities  would shrink corporate profits, while drug shares fell on  possible stricter scrutiny from regulators.
682567
Merrill Lynch downgraded Chiron (nasdaq: CHIR - news - people ) to &quot;sell&quot; from &quot;neutral&quot; after news reports indicated a flu vaccine from GlaxoSmithKline (nyse: GSK - news - people ) could be approved by the US Food and Drug Administration as early as
703528
Shares of Pharmos Corp.  fell 57 percent before the bell on Monday after the biopharmaceutical company said clinical trials showed its drug dexanabinol was not effective as a treatment for severe traumatic brain injury.
695798
Yet another delay from the FDA leaves investors hanging.
79138
Sanofi-Aventis has withdrawn its   marketing application for its Multaq heart arrhythmia treatment   in the European Union, the world's third-largest drugmaker said   on Thursday.
585414
Shares of Biovail Corp. fell Wednesday after the drug maker confirmed that a competitor had applied to the Food and Drug Administration to market a generic version of its extended-release antidepressant Wellbutrin XL.
277535
Shares of large U.S. and European drug makers fell on Thursday after a prominent cardiologist questioned the safety of new arthritis drugs and the performance of U.S. regulators in monitoring drug safety.
617822
The drug maker Sanofi-Aventis said its fourth-quarter profit fell 4.6 percent under pressure from European health care reforms and generic competition for its blockbuster medicines. It said earnings would be flat this year. The company, which is based in Paris, declined to comment on reports that it had discussed a merger with Bristol-Myers Squibb. Net profit at Sanofi-Aventis fell to 1.38 billion euros ($1.79 billion) in the fourth quarter from 1.44 billion euros a year earlier. Sales increased 5 percent, to 7.36 billion euros ($9.53 billion) from 7.01 billion euros.
73972
Shares of Syneron Medical Ltd., a maker of cosmetic medical devices, plunged 20 percent Tuesday morning following regulators&#39; rejection of its application for a cellulite-smoothing device.